You are not logged in.

Towards stage specific treatments: Effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia.

Rapado-Castro,M, Berk,M, Venugopal,K, Bush,AI, Dodd,S and Dean,OM 2015, Towards stage specific treatments: Effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia., Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 57, no. 3, pp. 69-75, doi: 10.1016/j.pnpbp.2014.10.002.

Attached Files
Name Description MIMEType Size Downloads

Title Towards stage specific treatments: Effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia.
Author(s) Rapado-Castro,M
Berk,MORCID iD for Berk,M orcid.org/0000-0002-5554-6946
Venugopal,K
Bush,AI
Dodd,SORCID iD for Dodd,S orcid.org/0000-0002-7918-4636
Dean,OMORCID iD for Dean,OM orcid.org/0000-0002-2776-3935
Journal name Progress in Neuro-Psychopharmacology and Biological Psychiatry
Volume number 57
Issue number 3
Start page 69
End page 75
Total pages 7
Publisher Elsevier
Place of publication Amsterdam, The Netherlands
Publication date 2015-03-03
ISSN 0364-7722
1878-4216
Keyword(s) N-acetyl cysteine
glutathione
neuroprogression
oxidative stress
schizophrenia
staging
Summary Schizophrenia is a chronic and often debilitating disorder in which stage of illness appears to influence course, outcome, prognosis and treatment response. Current evidence suggests roles for oxidative, neuroinflammatory, neurotrophic, apoptotic, mitochondrial and glutamatergic systems in the disorder; all targets of N-acetyl cysteine (NAC). A double blind, placebo controlled trial suggested NAC to be beneficial to those diagnosed with schizophrenia. The current manuscript aims to investigate duration of the illness as a key factor that may be modulating the response to NAC in the participants who took part in the study. A sample of 121 participants were randomized in a double fashion to 24weeks (placebo=62; NAC=59). Clinical and functional variables were collected over the treatment period. Duration of the illness at baseline was grouped into <10years, 10-<20years and >20years. Mixed Model Repeated Measures Analysis was used to explore the effect of illness duration on response to treatment with NAC. A significant interaction between duration of the illness and response to treatment with NAC was consistently found for positive symptoms and functional variables, but not for negative or general symptoms or for side effects related outcomes. The pattern of changes suggests this mediator effect of duration of illness in response to treatment is more evident in those participants with 20years or more of illness duration. Our results suggest a potential advantage of adjunctive NAC over placebo on functioning and positive symptoms reduction in those patients with chronic schizophrenia. This has potential for suggesting stage specific treatments.
Language eng
DOI 10.1016/j.pnpbp.2014.10.002
Field of Research 110999 Neurosciences not elsewhere classified
Socio Economic Objective 920410 Mental Health
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Persistent URL http://hdl.handle.net/10536/DRO/DU:30067184

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 8 times in TR Web of Science
Scopus Citation Count Cited 8 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 383 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Fri, 31 Oct 2014, 14:43:04 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.